Song et al., ACS Nano (2026) · SI Fig. S25, p16; Fig. S26e, pp16–17
Lipid stocks
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
RNA aqueous phase
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
Mixing and dilution
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
Final treatment / administration
Partial evidence; formulation correspondence unresolved
SI Fig. S25 compares the organ fractions of FLuc expression for screening formulations 1–16; exact fractions, animal strain/sex, dose and sampling time are not fully available from its caption. These are relative expression fractions, not absolute organ delivery.
Storage and use
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
- SI Fig. S25 compares the organ fractions of FLuc expression for screening formulations 1–16; exact fractions, animal strain/sex, dose and sampling time are not fully available from its caption. These are relative expression fractions, not absolute organ delivery.
Song et al., ACS Nano (2026) · SI Fig. S25, p16; Fig. S26e, pp16–17
Lipid stocks
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
RNA aqueous phase
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
Mixing and dilution
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
Final treatment / administration
Partial evidence; formulation correspondence unresolved
SI Fig. S26e measures serum cytokines 6 h after intravenous administration (n=3 biologically independent samples, mean ± SD). The available caption does not establish an sW3-versus-W3 cytokine advantage. Broad or clinical safety is not claimed.
Storage and use
The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.
- SI Fig. S26e measures serum cytokines 6 h after intravenous administration (n=3 biologically independent samples, mean ± SD). The available caption does not establish an sW3-versus-W3 cytokine advantage. Broad or clinical safety is not claimed.